NASDAQ:CYTK - Cytokinetics Stock Price, Price Target & More

$7.15 +0.05 (+0.70 %)

(As of 04/20/2018 04:00 PM ET)

Previous Close$7.15

Today's Range$7.05 - $7.30

52-Week Range$6.75 - $17.20

Volume165,718 shs

Average Volume370,366 shs

Market Capitalization$394.26 million

P/E Ratio-2.76

Dividend YieldN/A

Beta1.16

About Cytokinetics (NASDAQ:CYTK)

Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.

Receive CYTK News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:CYTK

CUSIPN/A

Webwww.cytokinetics.com

Phone650-624-3000

Debt

Debt-to-Equity Ratio0.29%

Current Ratio8.46%

Quick Ratio8.46%

Price-To-Earnings

Trailing P/E Ratio-2.76

Forward P/E Ratio-3.95

P/E GrowthN/A

Sales & Book Value

Annual Sales$13.37 million

Price / Sales28.88

Cash FlowN/A

Price / CashN/A

Book Value$2.04 per share

Price / Book3.50

Profitability

EPS (Most Recent Fiscal Year)($2.59)

Net Income$-127,790,000.00

Net Margins-172.27%

Return on Equity-96.95%

Return on Assets-41.65%

Miscellaneous

Employees137

Outstanding Shares54,010,000

How to Become a New Pot Stock Millionaire

Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

How were Cytokinetics' earnings last quarter?

Cytokinetics (NASDAQ:CYTK) posted its earnings results on Thursday, February, 15th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.71) by $0.04. The biopharmaceutical company earned ($0.02) million during the quarter, compared to the consensus estimate of $4.83 million. Cytokinetics had a negative return on equity of 96.95% and a negative net margin of 172.27%. View Cytokinetics' Earnings History.

When is Cytokinetics' next earnings date?

Cytokinetics is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for Cytokinetics.

What price target have analysts set for CYTK?

8 equities research analysts have issued 1-year price objectives for Cytokinetics' shares. Their forecasts range from $10.00 to $24.00. On average, they expect Cytokinetics' share price to reach $15.75 in the next twelve months. View Analyst Ratings for Cytokinetics.

What are Wall Street analysts saying about Cytokinetics stock?

Here are some recent quotes from research analysts about Cytokinetics stock:

1. Cantor Fitzgerald analysts commented, "Robert Califf, M.D. has joined CYTK’s Board of Directors (BoD), adding his expertise in cardiovascular and regulatory domains, we believe." (2/12/2018)
2. According to Zacks Investment Research, "Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. " (8/17/2017)
3. Cowen Inc analysts commented, "CYTK reported a Q2 loss of $29.1MM and ended the quarter with $332MM in cash." (8/4/2017)

Who are some of Cytokinetics' key competitors?

Some companies that are related to Cytokinetics include ARMO BioSciences (ARMO), Vanda Pharmaceuticals (VNDA), Deciphera Pharmaceuticals (DCPH), GlycoMimetics (GLYC), CymaBay Therapeutics (CBAY), NuCana (NCNA), OptiNose (OPTN), Omeros (OMER), Karyopharm Therapeutics (KPTI), ANI Pharmaceuticals (ANIP), Dova Pharmaceuticals (DOVA), AMAG Pharmaceuticals (AMAG), Adamas Pharmaceuticals (ADMS), Rocket Pharmaceuticals (RCKT), Endocyte (ECYT), Lannett (LCI), Ziopharm Oncology (ZIOP) and Rhythm Pharmaceuticals (RYTM).

Who are Cytokinetics' key executives?

Cytokinetics' management team includes the folowing people:

Robert I. Blum, President, Chief Executive Officer & Director
Ching Jaw, Chief Financial Officer & Senior Vice President
Andy Wolff, Chief Medical Officer & Senior Vice President
Bonnie A. Charpentier, Senior VP-Regulatory Affairs & Compliance
Peter S. Roddy, Chief Accounting Officer & Senior Vice President

Has Cytokinetics been receiving favorable news coverage?

Media coverage about CYTK stock has been trending somewhat positive on Friday, according to Accern Sentiment. The research group identifies negative and positive press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cytokinetics earned a media sentiment score of 0.05 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 45.43 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Cytokinetics?

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cytokinetics' stock price today?

One share of CYTK stock can currently be purchased for approximately $7.15.

How big of a company is Cytokinetics?

Cytokinetics has a market capitalization of $394.26 million and generates $13.37 million in revenue each year. The biopharmaceutical company earns $-127,790,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis. Cytokinetics employs 137 workers across the globe.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]

MarketBeat Community Rating for Cytokinetics (CYTK)

Community Ranking:		3.8 out of 5 ( )
Outperform Votes:		398 (Vote Outperform)
Underperform Votes:		129 (Vote Underperform)
Total Votes:		527

MarketBeat's community ratings are surveys of what our community members think about Cytokinetics and other stocks. Vote "Outperform" if you believe CYTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTK will underperform the S&P 500 over the long term. You may vote once every thirty days.

Cytokinetics (NASDAQ:CYTK) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

8 Wall Street analysts have issued ratings and price targets for Cytokinetics in the last 12 months. Their average twelve-month price target is $15.75, suggesting that the stock has a possible upside of 120.28%. The high price target for CYTK is $24.00 and the low price target for CYTK is $10.00. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.88	2.89	2.90	3.00
Ratings Breakdown:	0 Sell Rating(s) 1 Hold Rating(s) 7 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 9 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$15.75	$16.7778	$18.20	$22.30
Price Target Upside:	120.28% upside	116.49% upside	106.82% upside	44.34% upside

Cytokinetics (NASDAQ:CYTK) Consensus Price Target History

Price Target History for Cytokinetics (NASDAQ:CYTK)

Cytokinetics (NASDAQ:CYTK) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
2/21/2018	Morgan Stanley	Boost Price Target	Overweight -> Overweight	$17.00 -> $18.00	High
2/20/2018	Cowen	Reiterated Rating	Buy	$11.00	Medium
2/12/2018	Cantor Fitzgerald	Set Price Target	Hold	$10.00	Low
1/19/2018	HC Wainwright	Set Price Target	Buy	$20.00	High
11/29/2017	Needham & Company LLC	Downgrade	Strong-Buy -> Buy	$22.00 -> $12.00	Low
11/21/2017	JMP Securities	Reiterated Rating	Outperform	$17.00 -> $13.00	N/A
11/21/2017	Piper Jaffray	Reiterated Rating	Overweight	$18.00	N/A
10/6/2017	Seaport Global Securities	Reiterated Rating	Buy	$24.00	N/A
3/23/2017	Rodman & Renshaw	Reiterated Rating	Buy	$25.00	Medium
2/17/2017	FBR & Co	Reiterated Rating	Outperform	$24.00	N/A
10/28/2016	Roth Capital	Set Price Target	Buy	$22.00	N/A

(Data available from 4/20/2016 forward)

Cytokinetics (NASDAQ:CYTK) Earnings History and Estimates Chart

Earnings by Quarter for Cytokinetics (NASDAQ:CYTK)

Cytokinetics (NASDAQ:CYTK) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.81 EPS
Next Year EPS Consensus Estimate: $-1.92 EPS

Cytokinetics (NASDAQ CYTK) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
4/25/2018		($0.45)					N/A
2/15/2018	Q4 2017	($0.71)	($0.75)	$4.83 million	($0.02) million	View	Listen
10/26/2017	Q3 2017	($0.64)	($0.60)	$5.35 million	$6.18 million	View	N/A
8/2/2017	Q2 2017	($0.5730)	($0.60)	$5.28 million	$3.05 million	View	Listen
4/27/2017	Q1 2017	($0.11)	($0.62)	$5.08 million	$4.15 million	View	N/A
2/16/2017	Q416	($0.39)	$0.1640	$14.10 million	$33.14 million	View	Listen
10/27/2016	Q3	($0.2730)	$0.74	$6.67 million	$59.05 million	View	Listen
7/28/2016	Q2	($0.2750)	($0.29)	$7.80 million	$5.80 million	View	Listen
4/28/2016	Q1	($0.37)	($0.31)	$8.14 million	$8.42 million	View	Listen
2/16/2016	Q415	($0.32)	($0.24)	$10.49 million	$9.80 million	View	Listen
10/29/2015	Q315	($0.30)	($0.23)	$11.24 million	$7.90 million	View	Listen
7/29/2015	Q2	($0.28)	($0.27)	$4.00 million	$6.54 million	View	Listen
4/30/2015	Q1	($0.08)	($0.23)	$10.10 million	$4.40 million	View	Listen
2/12/2015	Q4	($0.17)	$0.23	$10.80 million	$21.80 million	View	Listen
10/30/2014	Q3	($0.27)	($0.16)	$6.50 million	$9.42 million	View	Listen
7/30/2014	Q2	($0.32)	($0.23)	$7.01 million	$7.80 million	View	Listen
5/6/2014	Q1	($0.34)	($0.27)	$7.69 million	$8.00 million	View	Listen
2/6/2014	Q4	($0.08)	$0.21	$19.14 million	$24.30 million	View	Listen
10/30/2013	Q3 2013	($0.09)	($0.43)	$15.77 million	$4.47 million	View	N/A
7/31/2013	Q2 2013	($0.55)	($0.58)	$4.36 million	$1.01 million	View	N/A
4/30/2013	Q1 2013	($0.54)	($0.54)	$0.92 million	$0.82 million	View	N/A
2/5/2013	Q4 2012	($0.60)	($0.42)			View	N/A
10/30/2012	Q3 2012	($0.60)	($0.42)			View	N/A
7/31/2012	Q2 2012	($0.72)	($0.78)			View	N/A
4/26/2012	Q1 2012	($0.84)	($0.78)			View	N/A
2/2/2012	Q4 2011	($0.78)	($0.88)			View	N/A
10/27/2011	Q3 2011	($1.14)	($0.88)			View	N/A
7/28/2011	Q2 2011	($0.66)	($1.39)			View	N/A
4/27/2011	Q1 2011	($1.14)	($1.08)			View	N/A
2/14/2011	Q4 2010	($1.32)	($1.01)			View	N/A
10/28/2010	Q3 2010	($1.26)	($1.15)			View	N/A
7/28/2010	Q2 2010	($1.20)	($1.19)			View	N/A
4/29/2010	Q1 2010	($1.20)	($1.18)			View	N/A
2/3/2010	Q4 2009	($1.32)	($1.20)			View	N/A
10/28/2009	Q3 2009	($1.32)	($0.82)			View	N/A
7/29/2009	Q2 2009	$3.06	$5.90			View	N/A
4/30/2009	Q1 2009	($1.20)	($1.24)			View	N/A
2/10/2009	Q4 2008	($2.28)	($1.31)			View	N/A
10/30/2008	Q3 2008	($2.16)	($1.67)			View	N/A
7/31/2008	Q2 2008	($2.04)	($1.87)			View	N/A
4/29/2008	Q1 2008	($1.92)	($1.69)			View	N/A
1/31/2008	Q4 2007	($2.52)	($1.61)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Cytokinetics (NASDAQ:CYTK) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Cytokinetics (NASDAQ CYTK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.10%
Institutional Ownership Percentage: 71.41%

Insider Trading History for Cytokinetics (NASDAQ:CYTK)

Institutional Ownership by Quarter for Cytokinetics (NASDAQ:CYTK)

Cytokinetics (NASDAQ CYTK) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/5/2018	Robert I Blum	CEO	Sell	4,000	$7.52	$30,080.00	182,701
1/16/2018	Caryn Gordon Mcdowell	Insider	Sell	2,709	$9.00	$24,381.00	15,077
11/2/2017	Caryn Gordon Mcdowell	Insider	Sell	4,260	$12.94	$55,124.40	17,982
11/1/2017	Fady Ibraham Malik	EVP	Sell	7,321	$13.39	$98,028.19	47,540
11/1/2017	Robert I Blum	CEO	Sell	5,000	$13.51	$67,550.00	70,180
10/6/2017	Caryn Gordon Mcdowell	Insider	Sell	13,181	$15.49	$204,173.69
10/2/2017	Robert I Blum	CEO	Sell	5,000	$14.59	$72,950.00
9/6/2017	Caryn Gordon Mcdowell	Insider	Sell	10,131	$14.60	$147,912.60	19,801
9/1/2017	Robert I Blum	CEO	Sell	5,000	$14.71	$73,550.00	79,785
8/31/2017	Bradley Paul Morgan	SVP	Sell	118,330	$15.00	$1,774,950.00	63,107
8/31/2017	Santo J Costa	Director	Sell	5,000	$15.00	$75,000.00	5,000
8/29/2017	Santo J Costa	Director	Sell	5,000	$14.00	$70,000.00	5,000
8/8/2017	Caryn Gordon Mcdowell	Insider	Sell	11,348	$12.47	$141,509.56	21,570
8/1/2017	Robert I Blum	CEO	Sell	5,000	$13.79	$68,950.00	84,785
7/3/2017	Robert I Blum	CEO	Sell	5,000	$12.14	$60,700.00	88,385
6/1/2017	Robert I Blum	CEO	Sell	5,000	$13.62	$68,100.00	94,785
12/29/2016	Fady Ibraham Malik	EVP	Sell	5,633	$12.36	$69,623.88	3,361
8/31/2015	L Patrick Gage	Director	Buy	1,000	$6.95	$6,950.00	30,000
8/20/2015	L Patrick Gage	Director	Buy	10,000	$6.55	$65,500.00	30,000
5/6/2015	L Patrick Gage	Director	Buy	10,000	$5.71	$57,100.00
3/11/2015	Andrew A Wolff	CMO	Sell	21,875	$7.80	$170,625.00
12/30/2014	Fady Ibraham Malik	SVP	Sell	21,630	$6.73	$145,569.90
5/9/2014	L Patrick Gage	Director	Buy	10,850	$4.09	$44,376.50	10,000
2/25/2014	Eastern Capital Ltd	major shareholder	Buy	500,000	$8.00	$4,000,000.00	2,883,845

(Data available from 1/1/2013 forward)

Cytokinetics (NASDAQ CYTK) News Headlines

Source:

Date	Headline
	Cytokinetics (CYTK) Set to Announce Quarterly Earnings on Wednesday www.americanbankingnews.com - April 18 at 3:44 AM
	Cytokinetics (CYTK) Stock Rating Upgraded by BidaskClub www.americanbankingnews.com - April 16 at 10:54 AM
	Cytokinetics (CYTK) Given a $26.00 Price Target at HC Wainwright www.americanbankingnews.com - April 13 at 7:15 PM
	Cytokinetics to Announce First Quarter Results on April 26, 2018 globenewswire.com - April 13 at 5:03 AM
	Cytokinetics to Announce First Quarter Results on April 26, 2018 finance.yahoo.com - April 13 at 5:03 AM
	Cytokinetics (CYTK) Receives Consensus Rating of "Hold" from Brokerages www.americanbankingnews.com - April 12 at 1:41 PM
	Insider Selling: Cytokinetics, Inc. (CYTK) CEO Sells 4,000 Shares of Stock www.americanbankingnews.com - April 6 at 7:33 PM
	Cytokinetics (CYTK) Stock Rating Upgraded by ValuEngine www.americanbankingnews.com - April 5 at 2:09 PM
	Cytokinetics (CYTK) Downgraded by TheStreet www.americanbankingnews.com - April 2 at 9:42 PM
	Edited Transcript of CYTK earnings conference call or presentation 15-Feb-18 9:30pm GMT finance.yahoo.com - April 1 at 5:00 AM
	Cytokinetics (CYTK) Cut to "Strong Sell" at ValuEngine www.americanbankingnews.com - March 29 at 11:18 PM
	Cytokinetics (CYTK) Rating Increased to Sell at BidaskClub www.americanbankingnews.com - March 24 at 1:11 PM
	Cytokinetics, Inc. (CYTK) Given Consensus Recommendation of "Buy" by Brokerages www.americanbankingnews.com - March 18 at 1:48 PM
	Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day finance.yahoo.com - February 28 at 3:13 PM
	Cytokinetics (CYTK) PT Raised to $18.00 www.americanbankingnews.com - February 21 at 5:30 PM
	Cytokinetics, Inc. (CYTK) Given Average Rating of "Buy" by Brokerages www.americanbankingnews.com - February 21 at 2:31 PM
	Cytokinetics (CYTK) Earns Buy Rating from Cowen www.americanbankingnews.com - February 20 at 8:26 PM
	Cytokinetics Sees Unusually Large Options Volume (CYTK) www.americanbankingnews.com - February 20 at 6:56 AM
	Cytokinetics (CYTK) Announces Earnings Results, Misses Estimates By $0.04 EPS www.americanbankingnews.com - February 16 at 11:40 AM
	Cytokinetics, Inc. Reports Fourth Quarter 2017 Financial Results - GlobeNewswire (press release) globenewswire.com - February 16 at 5:10 AM
	Cytokinetics reports 4Q loss finance.yahoo.com - February 16 at 5:10 AM
	Cytokinetics, Inc. Reports Fourth Quarter 2017 Financial Results finance.yahoo.com - February 16 at 5:10 AM
	Cytokinetics, Inc. (CYTK) Expected to Post Quarterly Sales of $4.83 Million www.americanbankingnews.com - February 16 at 3:46 AM
	Cytokinetics Earnings Outlook - Benzinga www.benzinga.com - February 15 at 3:10 PM
	Cytokinetics to Present at the RBC Capital Markets Global Healthcare Conference - GlobeNewswire (press release) globenewswire.com - February 15 at 5:10 AM
	Cytokinetics to Present at the RBC Capital Markets Global Healthcare Conference finance.yahoo.com - February 15 at 5:10 AM
	Analysts Expect Cytokinetics, Inc. (CYTK) Will Announce Earnings of -$0.71 Per Share www.americanbankingnews.com - February 14 at 5:16 PM
	Cytokinetics Names Robert Califf, M.D., to Board of Directors ... - GlobeNewswire (press release) www.globenewswire.com - February 14 at 3:09 PM
	Cytokinetics (CYTK) Names Robert Califf to Board of Directors www.streetinsider.com - February 13 at 3:07 PM
	Cytokinetics' (CYTK) Hold Rating Reiterated at Cantor Fitzgerald www.americanbankingnews.com - February 12 at 4:18 PM
	Cytokinetics (CYTK) Names Robert Califf to Board of Directors - StreetInsider.com www.streetinsider.com - February 12 at 3:07 PM
	Cytokinetics: Multiple Catalysts Could Help With Rebound - Seeking Alpha seekingalpha.com - February 7 at 5:15 AM
	Head to Head Survey: Loxo Oncology (LOXO) & Cytokinetics (CYTK) www.americanbankingnews.com - February 5 at 11:14 PM
	Cytokinetics to Announce Fourth Quarter Results on February 15 ... - GlobeNewswire (press release) globenewswire.com - February 3 at 3:06 PM
	Cytokinetics to Announce Fourth Quarter Results on February 15, 2018 finance.yahoo.com - February 3 at 5:05 AM
	Zacks: Brokerages Expect Cytokinetics, Inc. (CYTK) Will Announce Earnings of -$0.71 Per Share www.americanbankingnews.com - January 28 at 5:12 PM
	Cytokinetics, Inc. (CYTK) Receives Consensus Recommendation of "Buy" from Analysts www.americanbankingnews.com - January 27 at 2:00 PM
	Cytokinetics (CYTK) Given a $20.00 Price Target by HC Wainwright Analysts www.americanbankingnews.com - January 20 at 7:38 PM
	Cytokinetics (CYTK) PT Raised to $20 at HC Wainwright; 'The Year of CK-107' - StreetInsider.com www.streetinsider.com - January 20 at 3:16 PM
	Cytokinetics, Inc. (CYTK) Insider Caryn Gordon Mcdowell Sells 2,709 Shares www.americanbankingnews.com - January 18 at 9:58 PM
	Cantor Fitzgerald Reaffirms "Hold" Rating for Cytokinetics (CYTK) www.americanbankingnews.com - January 18 at 1:50 PM
	Zacks: Brokerages Anticipate Cytokinetics, Inc. (CYTK) Will Post Quarterly Sales of $4.83 Million www.americanbankingnews.com - January 13 at 5:00 AM
	Zacks: Brokerages Anticipate Cytokinetics, Inc. (CYTK) to Announce -$0.71 EPS www.americanbankingnews.com - January 11 at 7:32 PM
	BRIEF-Cytokinetics Announces Progress Against Vision 2020 www.reuters.com - January 3 at 8:50 AM
	Cytokinetics Announces Progress Against Vision 2020 finance.yahoo.com - January 3 at 8:50 AM
	$4.83 Million in Sales Expected for Cytokinetics, Inc. (CYTK) This Quarter www.americanbankingnews.com - December 28 at 8:32 PM
	Cytokinetics, Inc. (CYTK) Expected to Post Earnings of -$0.71 Per Share www.americanbankingnews.com - December 26 at 7:20 AM
	Contrasting Cytokinetics (CYTK) and Its Peers www.americanbankingnews.com - December 12 at 7:34 PM
	Cytokinetics further discusses tirasemtiv results; down 2.5% - Seeking Alpha seekingalpha.com - December 12 at 5:36 PM
	5 Stocks To Watch For December 11, 2017 - Benzinga www.benzinga.com - December 11 at 5:22 PM

Cytokinetics (NASDAQ:CYTK) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Cytokinetics (NASDAQ:CYTK) Income Statement, Balance Sheet and Cash Flow Statement

Cytokinetics (NASDAQ CYTK) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff